Associated Papers
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
SOX2 confers tumour permissiveness in a specific skin progenitor population.
Centeno PP et al.
Nature Communications, 2026
ClinMAVE: a curated database for clinical application of data from multiplexed assays of variant effect.
Ma C et al.
Nucleic Acids Research, 2026
Decoding the Mutational Hierarchy of Thyroid Cancer and Associated Signaling Pathways.
Nashier D et al.
Archives of Medical Research, 2026
Quantitative ctDNA Profiling of RAS Mutations as a Prognostic Biomarker in Metastatic Colorectal Cancer.
Chibaudel B et al.
International Journal of Molecular Sciences, 2025
Intrinsic resistance to RAS inhibitors is driven by dysregulation of KRAS degradation.
Ivanisevic T et al.
Nature Communications, 2025
Nucleotide Substitution Biases in Related Cancer Driver Genes.
Khadre A et al.
International Journal of Molecular Sciences, 2025
Evolving Features of RASopathies Among Pregnancies With Abnormal Fetal Fluid Collections.
Gulrajani NB et al.
Prenatal Diagnosis, 2025
Targeting distinct amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas.
Ohba S et al.
Acta Neuropathologica Communications, 2025
Genetic Heterogeneity of Undifferentiated Pleomorphic Sarcoma: Is There Potential for Targeted Therapy?
Lesovaya EA et al.
Cancers, 2025
Structural and allosteric effects of the membrane-bound PI3Kα H1047R mutation and opportunities for drug discovery.
Kotzampasi DM et al.
Communications Chemistry, 2025
Kinase suppressor of Ras 1 (KSR1) promotes liver carcinogenesis via activation of the RAS/RAF/MEK/ERK signaling pathway.
Moon H et al.
Jhep Reports : Innovation in Hepatology, 2025
Molecular Profiling of KRAS, NRAS, and BRAF in Colorectal Cancer: Insights From a Libyan Cohort.
Tawel HM et al.
Cureus, 2025
Functional Analysis of Rare RAS Variants of Unknown Significance.
Park S et al.
Cancer Research Communications, 2025
Somatic genetic alterations in the development and progression in thyroid tumors of follicular cells.
Calafato G et al.
European Thyroid Journal, 2025
Current states in understanding oligodendroglia-mediated neurological issues in neurofibromatosis type 1 (NF1).
Aghoghovwia BE et al.
Acta Neuropathologica Communications, 2025
Molecular Landscape, Genomic Shift, and Prediction in the Neoadjuvant Setting of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Pons L et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
PreMode predicts mode-of-action of missense variants by deep graph representation learning of protein sequence and structural context.
Zhong G et al.
Nature Communications, 2025
Resistance to BRAF inhibitors drives melanoma sensitivity to Chk1 inhibition.
Carvalho DG et al.
Pharmacological Research, 2025
Germline mutations in PPP2R1B in patients with a personal and family history of cancer.
Mazhar S et al.
Jci Insight, 2025
Targeting Hyperactive Ras Signaling in Pediatric Cancer.
Levinson A et al.
Cold Spring Harbor Perspectives in Medicine, 2025
Limited cell-autonomous anticancer mechanisms in long-lived bats.
Athar F et al.
Nature Communications, 2025
RAS Pathway Mutations and Therapeutics in Vascular Anomalies.
Alharbi S et al.
Pediatric Blood & Cancer, 2025
Variant effect predictor correlation with functional assays is reflective of clinical classification performance.
Livesey BJ et al.
Genome Biology, 2025
Aberrant ERK signaling in astrocytes impairs learning and memory in RASopathy-associated BRAF mutant mouse models.
Kang M et al.
The Journal of Clinical Investigation, 2025
Regional and Gender-Based Distribution of KRAS Mutations in Metastatic Colorectal Cancer Patients in Turkey: An Observational Study.
Ilhan N et al.
Medicina (kaunas, Lithuania), 2025
Genomic landscape and preclinical models of angiosarcoma.
Benton A et al.
Molecular Oncology, 2025
Impaired MC3T3-E1 osteoblast differentiation triggered by oncogenic HRAS is rescued by the farnesyltransferase inhibitor Tipifarnib.
Andrasch Y et al.
Scientific Reports, 2025
A Drosophila model for Costello Syndrome caused by Ras mutation K117R.
Karunaraj P et al.
Biorxiv : the Preprint Server for Biology, 2025
Engineered extrachromosomal oncogene amplifications promote tumorigenesis.
Pradella D et al.
Nature, 2025
Thyroid C-Cell Biology and Oncogenic Transformation.
Bagheri-Yarmand R et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer, 2025
Schimmelpenning-Feuerstein-Mims syndrome: a systematic review of clinical cases to identify genotype-phenotype associations.
Zelenova E et al.
Frontiers in Medicine, 2025
Case report & review: Bilateral NIFTP harboring concomitant HRAS and KRAS mutation: Report of an unusual case and literature review.
Brogna MR et al.
Molecular Carcinogenesis, 2024
Rasopathy-Associated Mutation Ptpn11D61Y has Age-Dependent Effect on Synaptic Vesicle Recycling.
Guhathakurta D et al.
Cellular and Molecular Neurobiology, 2024
Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma.
Wen Y et al.
Nature Communications, 2024
Mitochondrial double-stranded RNA homeostasis depends on cell-cycle progression.
Xavier V et al.
Life Science Alliance, 2024
Inhibition and degradation of NRAS with a pan-NRAS monobody.
Whaby M et al.
Oncogene, 2024
BubR1 and SIRT2: Insights into aneuploidy, aging, and cancer.
Pun R et al.
Seminars in Cancer Biology, 2024
Cancer risk assessment of premalignant breast tissues from patients with BRCA mutations by genome profiling.
Hirose T et al.
Npj Breast Cancer, 2024
Evolutionary origins and innovations sculpting the mammalian PRPS enzyme complex.
Karki BR et al.
Biorxiv : the Preprint Server for Biology, 2024
GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.
Ikeuchi H et al.
Oncogene, 2024
PPM1D activity promotes cellular transformation by preventing senescence and cell death.
Stoyanov M et al.
Oncogene, 2024